TUM and ITM join forces for precision therapies in cancer medicine

10/24/2024
Reading time 2 min.

In an effort to provide more targeted therapies for cancer patients, the Technical University of Munich (TUM), the TUM University Hospital, and ITM Isotope Technologies Munich SE have signed a research framework agreement. Through this partnership, the institutions aim to enhance their collaboration and involvement of the FRM II research reactor in the fields of nuclear medicine, radiopharmacy, and medical isotope technology.

Representatives from TUM and ITM visit the production laboratories.

TUM President Prof. Thomas F. Hofmann emphasized: "We need to accelerate the development of effective cancer therapies! This is why we are combining TUM’s excellence in natural sciences and medicine with the production of radioisotopes, such as Lutetium-177, at the FRM II research reactor, alongside ITM’s expertise as a leading radiopharmaceutical biotech company in the development and manufacturing of medical radiotherapeutics and diagnostics, and the top-tier medical care provided by our TUM University Hospital. Together, we aim to develop innovative radionuclide therapies for targeted cancer treatment, significantly improving treatment outcomes and quality of life for cancer patients."

Dr. Andrew Cavey, CEO of ITM, said: "TUM is a global leader in merging top-tier research, scientific innovation, and entrepreneurship. This agreement is the culmination of two decades of collaboration with TUM, and it will provide us with valuable access to their world-class institutes and clinics, advancing pioneering research in nuclear medicine. As we expand our pipeline of targeted radiopharmaceuticals, we look forward to working on future projects with TUM to further develop new treatment options for cancer patients."

Prof. Stephanie Combs, Dean of the TUM School of Medicine and Health and Board Member of the TUM University Hospital, stated: "In the interdisciplinary fight against cancer, nuclear medicine plays a particularly significant role. It is crucial for imaging the disease and its innovative treatment methods open up new opportunities for patients. That is why we are committed to researching new approaches. The unique collaboration between TUM and ITM offers unparalleled opportunities to combine ITM’s leading position in radioisotope production and drug development with the research expertise of our university hospital. I am very excited to provide our patients with the latest scientific advancements."

Further information and links

Über ITM Isotope Technologies Munich SE

ITM mit Hauptsitz in Garching bei München und einer Niederlassung in den USA, ist ein führendes radiopharmazeutisches Biotech-Unternehmen, das es sich zur Aufgabe gemacht hat, eine neue Generation radiomolekularer Präzisionstherapeutika und -diagnostika für schwer behandelbare Tumore zu entwickeln. Ihr Ziel ist es, die Bedürfnisse von Krebspatienten, Ärzten und unseren Partnern durch die Entwicklung, Produktion und weltweite Bereitstellung hochwertiger Produkte zu erfüllen. Sie entwickeln eine breite Pipeline an Diagnostika und Therapeutika gegen Krebs.

Technical University of Munich

Corporate Communications Center